Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 Combined With Rapamycin in Sjögren's Syndrome
NCT05605665Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin, sirolimus in Sjögren's syndrome, sponsored by Peking University People's Hospital. Started Dec 2022; status: completed.
02
Drugs
aldesleukinsirolimus
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT05605665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605665.